Email this article The correlation between Serum phospholipase A2 receptor antibody and clinicopathological features in patients with membranous nephropathy
Vol 5, Issue 2.1, 2021
VIEWS - 42 (Abstract) 32 (PDF)
Abstract
Objective: To assess the correlation between Serum phospholipase A2 receptor antibody and clinicopathological features in patients with membranous nephropathy. Method: The patients being hospitalized for renal biopsy were selected in this study from January 2016 to January 2018. And normal controls were randomly selected; all the patients were divided into idiopathic membranous nephropathy and non-idiopathic membranous nephropathy groups; patients with idiopathic membranous nephropathy were divided into three groups, namely stage I, stage II and stage III; using software for statistical analysis. Results: A total of 357 patients were enrolled, including 155 patients with idiopathic membranous nephropathy, 183 patients with non-idiopathic membranous nephropathy, and 19 cases for normal controls. The average age of the idiopathic membranous nephropathy (IMN) group is higher than that of the membranous nephropathy group (P = 0.01). Different pathological stages of idiopathic membranous nephropathy general clinical characteristics analysis results showed that the age, cys c, serum creatinine (Scr) in stage III membranous nephropathy group were higher than those of the stage I and II membranous nephropathy (P values were 0.003, 0.000 and 0.000 respectively); titers of serum phospholipase A2 receptors antibody with stage II and III membranous nephropathy higher than the stage I membranous nephropathy group (P = 0.006); serum albumin (Alb) levels correlated inversely with serum anti-PLA2R antibody titers (rs = –0.234, P = 0.003), serum antiphospholipase A2 receptor (PLA2R) antibody titer level in patients with idiopathic membranous nephropathy was significantly higher than that in patients with non-membranous nephropathy (P < 0.001). Conclusion: Baseline titer of serum anti-PLA2R antibody is negatively correlated with Alb in the IMN patients，and serum anti-PLA2R antibody level in patients with stage I IMN was significantly lower than stage II and III IMN patients.
Keywords
Full Text:
PDFReferences
1. Wang H. Nephrology (in Chinese). 3rd ed. Beijing: People’s Medical Publishing House; 2008. p. 1032–1042.
2. Lai W, Yeh T, Chen P, et al. Membranous nephropathy: A review on the pathogenesis, diagnosis, and treatment. Journal of the Formosan Medical Association 2015; 114(2): 102–111.
3. Beck LH, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. The New England Journal of Medicine 2009; 361(1): 11–21.
4. Qin W, Beck LH, Zeng C, et al. Anti-phospholipase A2 Receptor antibody in membranous nephropathy. Journal of the American Society of Nephrology 2011; 22(6): 1137–1143.
5. Ehrenreich T, Chung J. Pathology of membranous nephropathy. Patho Annu 1968; 3: 145–186.
6. Couser WG. Primary membranous nephropathy. Clinical Journal of the American Society of Nephrology Cjasn 2017; 12(6): 983.
7. Heymann W, Hackel DB, Harwood S, et al. Production of nephrotic syndrome in rats by Freund’s adjuvants and rat kidney suspensions. Experimental Biology & Medicine 1959; 100: 660–664.
8. Hoxha E, Harendza S, Pinnschmidt H, et al. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clinical Journal of the American Society of Nephrology Cjasn 2014; 9(11): 1883–1890.
9. Kei H, Masayuki I, Shohei T, et al. Anti-phospholipase A2 receptor (PLA2R) antibody and glomerular PLA2R expression in Japanese patients with membranous nephropathy. Plos One 2016; 11(6): e0158154.
10. Yun J, Yang S, Dong K, et al. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. Plos One 2013; 8(4): e62151.
11. Qin H, Zhang M, Le W, et al. Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy. Journal of the American Society of Nephrology 2016; 27(10): 3195–3203.
12. Ramachandran R, Kumar V, Kumar A, et al. PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplantation Association-European Renal Association 2016; 31(9): 1486–1493.
13. Radice A, Trezzi B, Maggiore U, et al. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmunity Reviews 2016; 15(2): 146–154.
14. Jullien P, Barbara SP, Maillard N, et al. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy. Clinical Kidney Journal 2017; 10(2): 209–214.
15. Zhou G, Jin L, Yu J, et al. Correlation between serum anti PLA2R antibody and disease condition in adult patients with membranous nephropathy (in Chinese). Chinese Journal of Nephrology 2012; 28(2): 111–114.
16. Yuan L, Shi L, Xu Y, et al. Clinical significance of anti-M type phospholipase A2 receptor antibody in treatment of idiopathic membranous nephropathy. Chinese Journal of Clinical Laboratory Science 2015; 33 (8): 581–585.
17. Ping Z, Fu D Z, Su X, et al. Increasing frequency of idiopathic membranous nephropathy in primary glomerular disease: A 10-year renal biopsy study from a single Chinese nephrology centre. Nephrology 2015; 20 (8): 560–566.
18. Cattran DC. Idiopathic membranous glomerulonephritis. Kidney International 2001; 59(5): 1983–1994.
DOI: https://doi.org/10.24294/ti.v5.i2.1.1369
Refbacks
- There are currently no refbacks.
Copyright (c) 2021 Qipeng Huang, Gaosi Xu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This site is licensed under a Creative Commons Attribution 4.0 International License.